Research programme: Immunological disorder therapeutics - Karma Biotechnologies
Alternative Names: Xavines™Latest Information Update: 28 Apr 2026
At a glance
- Originator Karma Biotechnologies
- Class Antiallergics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Food hypersensitivity; Hypersensitivity
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for research development in Allergy in USA (Parenteral)
- 28 Apr 2026 No recent reports of development identified for research development in Food-hypersensitivity in USA (Parenteral)
- 28 Mar 2026 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)